Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
55.45
-2.11 (-3.67%)
At close: Apr 9, 2026
Market Cap25.76B +35.3%
Revenue (ttm)801.14M +122.6%
Net Income-764.05M
EPS-1.71
Shares Out464.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,195,707
Average Volume4,536,772
Open57.00
Previous Close57.56
Day's Range55.00 - 58.36
52-Week Range43.12 - 86.18
Beta-0.02
RSI53.39
Earnings DateMar 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan... [Read more]

Sector Healthcare
Founded 2017
Employees 985
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements